Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3233 - Biweekly TAS-102 and Bevacizumab as a Third-Line Chemotherapy for metastatic colorectal cancer: A Phase II Multicenter Clinical Trial (TAS-CC4 study)


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Yoichiro Yoshida


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


Y. Yoshida1, T. Yamada2, H. Matsuoka3, K. Hirata4, H. Kuramochi5, C. Kosugi6, M. Takahashi7, A. Fukazawa8, H. Sonoda9, A. Matsuda10, T. Watanabe11, M. Koizumi12, N. Aisu1, S. Hasegawa1, H. Yoshida2, K. Sakamoto7, H. Ishida13, K. Koda6

Author affiliations

  • 1 Gastroenterological Surgery, Fukuoka University School of Medicine, 814-0180 - FUKUOKA/JP
  • 2 Department Of Gastroenterological Surgery, Nippon Medical University, Tokyo/JP
  • 3 Surgery, Fujita Health University, 4701192 - Toyoake/JP
  • 4 Department Of Surgery 1, University of Occupational & Environmental Health, Fukuoka/JP
  • 5 Department Of Chemotherapy And Palliative Care, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba/JP
  • 6 Department Of Surgery, Teikyo University Chiba Comprehensive Medical Center, Chiba/JP
  • 7 Department Of Coloproctological Surgery, Juntendo University School of Medicine, Tokyo/JP
  • 8 Gastroenterological Surgery, Iwata City Hospital, Shizuoka/JP
  • 9 Department Of Gastroenterological Surgery, Shiga Medical University, Shiga/JP
  • 10 Surgery, Nippon Medical School Chiba Hokusoh Hospital, 270-1694 - Inzai/JP
  • 11 Third Department Of Internal Medicine, University of Occupational & Environmental Health, Fukuoka/JP
  • 12 Digestive Surgery, Nippon Medical School Hospital, 113-8603 - Tokyo/JP
  • 13 Department Of Digestive Tract And General Surgery, Saitama Medical University, Saitama/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3233


TAS-102 improved overall survival of metastatic colorectal cancer (mCRC) patients with median progression-free survival (PFS) of 2.0 months (RECOURSE trial). Subsequently, the combination of TAS-102 and bevacizumab (BV) has been shown to extend median PFS to 3.7 months (C-TASK FORCE). However, this study included patients with 2nd line and 3rd line chemotherapy. Furthermore, combination chemotherapy of TAS-102 plus BV was reportedly associated with grade ≥3 neutropenia in 72% of treated patients. This study was designed for patients being treated as 3rd line chemotherapy to investigate the clinical impact of this combination and whether neutropenia could be suppressed by altering the TAS-102 administration protocol (biweekly method).


This phase II study was conducted in investigator-initiated, open-label, single-arm, multicenter manner in Japan. Eligible patients were 20-80 years old and had to have an ECOG performance status of 0 or 1; had confirmed unresectable mCRC with histologically diagnosed adenocarcinoma; had previously administrated first- and second-line chemotherapy for mCRC and whose tumors were diagnosed as progression of disease (PD). TAS-102 (35 mg/ m²) was given orally twice daily on days 1 -5 and 15 -19 in a 4-weeks cycle, and BV (5 mg/ kg) was administered by intravenous infusion for 30 min in every 2 weeks. The primary endpoint was PFS, and the secondary endpoints were response rate (RR), disease control rate (DCR), overall survival (OS), and safety. This study was registered at the University Hospital Medical Information Network, as UMIN#000030030.


Between January 1, 2018, and March 31, 2019, 45 patients with mCRC were enrolled in this study (median age, 63; male, 51%). The median PFS was 121 days. The RR and DCR were 4.4% and 73.3%, respectively. Grade 3 or higher adverse events were hypertension (20.0%), neutropenia (15.5 %), leukopenia (6.7 %), fatigue (6.7 %), anemia (4.4 %), anorexia (2.2 %), nausea (2.2 %), creatinine increased (2.2 %) and proteinuria (2.2 %). No treatment-related deaths occurred.


Biweekly administration of TAS-102 and BV prevents neutropenia and could be one of the treatment options for 3rd line chemotherapy for mCRC.

Clinical trial identification

UMIN000030030. 2018/March/01.

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.